PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
PTC Therapeutics, Inc. (PTCT)
Last ptc therapeutics, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ptcbio.com
Company Research
Source: PR Newswire
– Full-year 2025 product and royalty revenue of $831M, exceeding guidance –– Strong Sephience™ (sepiapterin) uptake since 2H 2025 launch with fourth quarter and 2025 revenue of $92M and $111M, respectively –– Cash of $1.95B as of December 31, 2025 –WARREN, N.J., Feb. 19, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2025. "We delivered another strong quarter and finish to 2025, building on the successful global launch of Sephience," said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics. "With our robust commercial engine, innovative R&D programs, and strong financial position, we look forward to continued success as we approach cash flow breakeven."Key Corporate Highlights Full-year 2025 product and royalty revenue of $831 million, exceeding guidanceGlobal launch of Sephience off to strong startQ4 2025 revenue of $92 million, including $81
Show less
Read more
Impact Snapshot
Event Time:
PTCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTCT alerts
High impacting PTC Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PTCT
News
- Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing [Yahoo! Finance]Yahoo! Finance
- Global Ferroptosis Targeting Therapy Market Opportunity Report 2026: Therapeutic Approaches, Technology Development Platforms & Clinical Trials Insights By Company, Country, Indication & Phase [Yahoo! Finance]Yahoo! Finance
- PTC Therapeutics to Participate at Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- PTC Therapeutics (NASDAQ:PTCT) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
- PTC Therapeutics to Participate at Upcoming Investor ConferencesPR Newswire
PTCT
Earnings
- 2/19/26 - Miss
PTCT
Sec Filings
- 3/5/26 - Form 144
- 3/5/26 - Form 144
- 3/5/26 - Form 144
- PTCT's page on the SEC website